HBXIP Overexpression is Correlated with the Clinical Features and Survival Outcome of Ovarian Cancer

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2017 Apr 9

PMID 28388957

Citations 7

Authors

Yixuan Wang

Jie Sun

Nan Li

Shuanlong Che

Tiefeng Jin

Shuangping Liu

Zhenhua Lin

Affiliations

Soon will be listed here.

Abstract

Background: Accumulated evidence has demonstrated that Mammalian hepatitis B X-interacting protein (HBXIP) has broad roles in cancer. Although HBXIP is associated with a variety of cancers, the HBXIP protein expression level and its clinical significance in ovarian cancer have not yet been determined. The aim of this study is to investigate the association between HBXIP expression and the clinicopathological features of ovarian cancer patients to determine whether HBXIP may be correlated with a poor prognosis in ovarian cancer patients.

Methods: HBXIP protein expression was assessed in a well-characterized series of ovarian cancer tissue samples (n = 120) with long-term follow-up, using immunohistochemistry to determine the location pattern and expression of HBXIP in ovarian cancer. The localization of HBXIP was detected in SKOV-3 ovarian cancer cells using immunofluorescence (IF) staining. The relationship between high HBXIP expression and the clinicopathological features of ovarian cancer patients was analyzed by Chi-square and Fisher's exact test. Overall survival (OS) rates of all the ovarian cancer patients were calculated using the Kaplan-Meier method, and univariate and multivariate analyses were performed using the Cox proportional hazards regression model.

Results: IF staining revealed strongly positive signals for HBXIP in both cytoplasm and nucleus, but mainly in the cytoplasm of SKOV-3 ovarian cancer cells. High HBXIP expression was predominantly observed in ovarian cancer tissues but not the adjacent non-tumor ovarian tissues. The strongly positive rate of HBXIP expression was 60.0% (72/120) in ovarian cancer and was significantly higher than in adjacent non-tumor tissues (17.4%, 4/23) (P = 0.000). High HBXIP expression was positively correlated with the occurrence of lymph node metastases (P = 0.025), histological grade (P = 0.036) and clinical stage (P = 0.003). The patients with high HBXIP expression had lower overall survival (OS) rates. Moreover, multivariate analysis indicated that HBXIP, in addition to the clinical stage, was a significant independent prognostic factor in patients with ovarian cancer.

Conclusions: High-level expression of HBXIP is associated with the progression of ovarian cancer and may be an effective biomarker for poor prognostic evaluation as well as a potential molecular therapy target for ovarian cancer patients.

Citing Articles

Research progress on oncoprotein hepatitis B X‑interacting protein (Review).

Cheng L, Guo L, Zou T, Yang Y, Tao R, Liu S Mol Med Rep. 2024; 29(6).

PMID: 38577934 PMC: 11019400. DOI: 10.3892/mmr.2024.13213.

Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Liu S, Wu M, Wang F J Cancer. 2021; 12(13):3976-3996.

PMID: 34093804 PMC: 8176232. DOI: 10.7150/jca.47695.

Germacrone Regulates HBXIP-Mediated Cell Cycle, Apoptosis and Promotes the Formation of Autophagosomes to Inhibit the Proliferation of Gastric Cancer Cells.

Fang X, Tan T, Gao B, Zhao Y, Liu T, Xia Q Front Oncol. 2020; 10:537322.

PMID: 33244453 PMC: 7683780. DOI: 10.3389/fonc.2020.537322.

Increased Expression of LAMTOR5 Predicts Poor Prognosis and Is Associated with Lymph Node Metastasis of Head and Neck Squamous Cell Carcinoma.

Yang Q, Wu C, Cao L, Xiao Y, Li H, Liu B Int J Med Sci. 2019; 16(6):783-792.

PMID: 31337951 PMC: 6643113. DOI: 10.7150/ijms.33415.

The oncoprotein HBXIP facilitates metastasis of hepatocellular carcinoma cells by activation of MMP15 expression.

Zheng S, Wu H, Wang F, Lv J, Lu J, Fang Q Cancer Manag Res. 2019; 11:4529-4540.

PMID: 31191014 PMC: 6529033. DOI: 10.2147/CMAR.S198783.

References

Yeung T, Leung C, Yip K, Yeung C, Wong S, C Mok S . Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. Am J Physiol Cell Physiol. 2015; 309(7):C444-56. PMC: 4593771. DOI: 10.1152/ajpcell.00188.2015. View

Liu S, Li L, Zhang Y, Zhang Y, Zhao Y, You X . The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells. J Biol Chem. 2012; 287(36):30228-39. PMC: 3436276. DOI: 10.1074/jbc.M112.343947. View

Minczuk M, Mroczek S, Pawlak S, Stepien P . Human ATP-dependent RNA/DNA helicase hSuv3p interacts with the cofactor of survivin HBXIP. FEBS J. 2005; 272(19):5008-19. DOI: 10.1111/j.1742-4658.2005.04910.x. View

Wang F, Sha L, Zhang W, Wu L, Qiao L, Li N . Involvement of hepatitis B X-interacting protein (HBXIP) in proliferation regulation of cells. Acta Pharmacol Sin. 2007; 28(3):431-8. DOI: 10.1111/j.1745-7254.2007.00531.x. View

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Melegari M, Scaglioni P, Wands J . Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. J Virol. 1998; 72(3):1737-43. PMC: 109461. DOI: 10.1128/JVI.72.3.1737-1743.1998. View

Bar-Peled L, Schweitzer L, Zoncu R, Sabatini D . Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell. 2012; 150(6):1196-208. PMC: 3517996. DOI: 10.1016/j.cell.2012.07.032. View

Shi H, Li Y, Feng G, Li L, Fang R, Wang Z . The oncoprotein HBXIP up-regulates FGF4 through activating transcriptional factor Sp1 to promote the migration of breast cancer cells. Biochem Biophys Res Commun. 2016; 471(1):89-94. DOI: 10.1016/j.bbrc.2016.01.174. View

Li H, Liu Q, Wang Z, Fang R, Shen Y, Cai X . The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer. J Biol Chem. 2015; 290(37):22649-61. PMC: 4566238. DOI: 10.1074/jbc.M115.658468. View

10.

Liu Q, Bai X, Li H, Zhang Y, Zhao Y, Zhang X . The oncoprotein HBXIP upregulates Lin28B via activating TF II D to promote proliferation of breast cancer cells. Int J Cancer. 2013; 133(6):1310-22. DOI: 10.1002/ijc.28154. View

11.

Yue L, Li L, Liu F, Hu N, Zhang W, Bai X . The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cells. Carcinogenesis. 2013; 34(4):927-35. PMC: 3616668. DOI: 10.1093/carcin/bgs399. View

12.

Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I . HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 2003; 22(11):2729-40. PMC: 156760. DOI: 10.1093/emboj/cdg263. View

13.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

14.

Liu F, Zhang W, You X, Liu Y, Li Y, Wang Z . The oncoprotein HBXIP promotes glucose metabolism reprogramming via downregulating SCO2 and PDHA1 in breast cancer. Oncotarget. 2015; 6(29):27199-213. PMC: 4694983. DOI: 10.18632/oncotarget.4508. View

15.

Wang F, Fei H, Qi B, Yao S, Chang Z . Overexpression of hepatitis B x-interacting protein in HepG2 cells enhances tumor-induced angiogenesis. Mol Cell Biochem. 2012; 364(1-2):165-71. DOI: 10.1007/s11010-011-1215-5. View

16.

Liu F, You X, Wang Y, Liu Q, Liu Y, Zhang S . The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF. Carcinogenesis. 2014; 35(5):1144-53. DOI: 10.1093/carcin/bgu021. View

17.

Li L, Liu B, Zhang X, Ye L . The oncoprotein HBXIP promotes migration of breast cancer cells via GCN5-mediated microtubule acetylation. Biochem Biophys Res Commun. 2015; 458(3):720-725. DOI: 10.1016/j.bbrc.2015.02.036. View

18.

Zhang Y, Zhao Y, Li L, Shen Y, Cai X, Zhang X . The oncoprotein HBXIP upregulates PDGFB via activating transcription factor Sp1 to promote the proliferation of breast cancer cells. Biochem Biophys Res Commun. 2013; 434(2):305-10. DOI: 10.1016/j.bbrc.2013.02.123. View

19.

Zhang M, Zhuang G, Sun X, Shen Y, Zhao A, Di W . Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics. J Ovarian Res. 2015; 8:67. PMC: 4618052. DOI: 10.1186/s13048-015-0195-6. View

20.

Xu F, You X, Liu F, Shen X, Yao Y, Ye L . The oncoprotein HBXIP up-regulates Skp2 via activating transcription factor E2F1 to promote proliferation of breast cancer cells. Cancer Lett. 2013; 333(1):124-32. DOI: 10.1016/j.canlet.2013.01.029. View